IL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain-Barré syndrome

Mediators of Inflammation

Volumn 2012, Issue , 2012, Pages

  Li, Shujuan ^a   Yu, Ming ^b   Li, Haifeng ^c   Zhang, Hongliang ^a   Jiang, Yanfang ^a  

^a JILIN UNIVERSITY   (China)

^b JIANGSU UNIVERSITY   (China)

^c QINGDAO UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN DERIVATIVE; INTERLEUKIN-22;

ADULT; AGED; ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE ANTIBODY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; HUMAN TISSUE; INFLAMMATION; MALE; NERVOUS SYSTEM; PATHOGENESIS; PERIPHERAL NERVOUS SYSTEM; PLASMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; TH17 CELL; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; METABOLISM; MIDDLE AGED;

ADULT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GUILLAIN-BARRE SYNDROME; HUMANS; INTERLEUKIN-17; INTERLEUKINS; MALE; MIDDLE AGED; TH17 CELLS; YOUNG ADULT;

EID: 84867921583     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2012/260473     Document Type: Article

References (33)

1. Hughes R. A., Cornblath D. R., Guillain-Barré syndrome. The Lancet 2005 366 9497 1653 1666 2-s2.0-27644558148 10.1016/S0140-6736(05)67665-9 (Pubitemid 41552422)
2. Cosi V., Versino M., Guillain-Barré syndrome. Neurological Sciences 2006 27 supplement 1 s47 s51 2-s2.0-33646764893 10.1007/s10072-006- 0548-4
3. Van Doorn P. A., Ruts L., Jacobs B. C., Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. The Lancet Neurology 2008 7 10 939 950 2-s2.0-51449103646 10.1016/S1474-4422(08)70215-1
4. Perry J. R., Fung A., Poon P., Bayer N., Magnetic resonance imaging of nerve root inflammation in the Guillain-Barre syndrome. Neuroradiology 1994 36 2 139 140 2-s2.0-0027953331 (Pubitemid 24040266)
5. Hughes R. A., Raphaël J. C., Swan A. V., van Doorn P. A., Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2006 1 CD002063 2-s2.0-33645521027
6. Raphaël J. C., Chevret S., Hughes R. A., Annane D., Plasma exchange for Guillain-Barré syndrome. Cochrane Database of Systematic Reviews 2002 2 CD001798 2-s2.0-0036046319
7. Miossec P., IL-17 and Th17 cells in human inflammatory diseases. Microbes and Infection 2009 11 5 625 630 2-s2.0-67349234068 10.1016/j.micinf.2009.04.003
8. Gurney A. L., IL-22, a Th1 cytokine that targets the pancreas and select other peripheral tissues. International Immunopharmacology 2004 4 5 669 677 2-s2.0-2142659288 10.1016/j.intimp.2004.01.016 (Pubitemid 38553887)
9. Aujla S. J., Chan Y. R., Zheng M., Fei M., Askew D. J., Pociask D. A., Reinhart T. A., McAllister F., Edeal J., Gaus K., Husain S., Kreindler J. L., Dubin P. J., Pilewski J. M., Myerburg M. M., Mason C. A., Iwakura Y., Kolls J. K., IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nature Medicine 2008 14 3 275 281 2-s2.0-40049098958 10.1038/nm1710 (Pubitemid 351347908)
10. Zheng Y., Valdez P. A., Danilenko D. M., Hu Y., Sa S. M., Gong Q., Abbas A. R., Modrusan Z., Ghilardi N., De Sauvage F. J., Ouyang W., Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nature Medicine 2008 14 3 282 289 2-s2.0-40049083827 10.1038/nm1720 (Pubitemid 351347912)
11. Zenewicz L. A., Flavell R. A., Recent advances in IL-22 biology. International Immunology 2011 23 3 159 163 2-s2.0-79952584368 10.1093/intimm/dxr001
12. Matusevicius D., Kivisäkk P., He B., Kostulas N., Özenci V., Fredrikson S., Link H., Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Multiple Sclerosis 1999 5 2 101 104 2-s2.0-0344389016 (Pubitemid 29186827)
13. Metawi S. A., Abbas D., Kamal M. M., Ibrahim M. K., Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clinical Rheumatology 2011 30 9 1201 1207 2-s2.0-79952987520 10.1007/s10067-011-1737-y
14. Fujino S., Andoh A., Bamba S., Ogawa A., Hata K., Araki Y., Bamba T., Fujiyama Y., Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003 52 1 65 70 2-s2.0-0037216498 10.1136/gut.52.1.65 (Pubitemid 36020767)
15. Lo Y. H., Torii K., Saito C., Furuhashi T., Maeda A., Morita A., Serum IL-22 correlates with psoriatic severity and serum IL-6 correlates with susceptibility to phototherapy. Journal of Dermatological Science 2010 58 3 225 227 2-s2.0-77953128344 10.1016/j.jdermsci.2010.03.018
16. Brand S., Beigel F., Olszak T., Zitzmann K., Eichhorst S. T., Otte J. M., Diepolder H., Marquardt A., Jagla W., Popp A., Leclair S., Herrmann K., Seiderer J., Ochsenkühn T., Göke B., Auernhammer C. J., Dambacher J., IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. American Journal of Physiology 2006 290 4 G827 G838 2-s2.0-33645829078 10.1152/ajpgi.00513.2005
17. Beyeen A. D., Adzemovic M. Z., Öckinger J., Stridh P., Becanovic K., Laaksonen H., Lassmann H., Harris R. A., Hillert J., Alfredsson L., Celius E. G., Harbo H. F., Kockum I., Jagodic M., Olsson T., IL-22RA2 associates with multiple sclerosis and macrophage effector mechanisms in experimental neuroinflammation. Journal of Immunology 2010 185 11 6883 6890 2-s2.0-78650673588 10.4049/jimmunol.1001392
18. Asbury A. K., Cornblath D. R., Assessment of current diagnostic criteria for Guillain-Barre syndrome. Annals of Neurology 1990 27 supplement 1 S21 S24 2-s2.0-0025375133 10.1002/ana.410270707 (Pubitemid 20178648)
19. Hughes R. A. C., Newsom-Davis J. M., Perkin G. D., Pierce J. M., Controlled trial of prednisolone in acute polyneuropathy. The Lancet 1978 2 8093 750 753 2-s2.0-0018119702 (Pubitemid 9034500)
20. Iwakura Y., Ishigame H., Saijo S., Nakae S., Functional specialization of interleukin-17 family members. Immunity 2011 34 2 149 162 2-s2.0-79951743212 10.1016/j.immuni.2011.02.012
21. Wolk K., Witte E., Witte K., Warszawska K., Sabat R., Biology of interleukin-22. Seminars in Immunopathology 2010 32 1 17 31 2-s2.0-77949656872 10.1007/s00281-009-0188-x
22. Ikeuchi H., Kuroiwa T., Hiramatsu N., Kaneko Y., Hiromura K., Ueki K., Nojima Y., Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis and Rheumatism 2005 52 4 1037 1046 2-s2.0-17244381180 10.1002/art.20965 (Pubitemid 40530109)
23. Zhang H. L., Azimullah S., Zheng X. Y., IFN- γ deficiency exacerbates experimental autoimmune neuritis in mice despite a mitigated systemic Th1 immune response. Journal of Neuroimmunology 2012 246 1-2 18 26
24. Zhang Z., Zhang Z. Y., Schluesener H. J., Compound A, a plant origin ligand of glucocorticoid receptors, increases regulatory T cells and M2 macrophages to attenuate experimental autoimmune neuritis with reduced side effects. Journal of Immunology 2009 183 5 3081 3091 2-s2.0-70349247894 10.4049/jimmunol.0901088
25. Chi L. J., Xu W. H., Zhang Z. W., Huang H. T., Zhang L. M., Zhou J., Distribution of Th17 cells and Th1 cells in peripheral blood and cerebrospinal fluid in chronic inflammatory demyelinating polyradiculoneuropathy. Journal of the Peripheral Nervous System 2010 15 4 345 356 2-s2.0-78650815791 10.1111/j.1529-8027.2010.00294.x
26. Ghoreschi K., Laurence A., Yang X. P., Tato C. M., McGeachy M. J., Konkel J. E., Ramos H. L., Wei L., Davidson T. S., Bouladoux N., Grainger J. R., Chen Q., Kanno Y., Watford W. T., Sun H. W., Eberl G., Shevach E. M., Belkaid Y., Cua D. J., Chen W., O'Shea J. J., Generation of pathogenic TH 17 cells in the absence of TGF- β 2 signalling. Nature 2010 467 7318 967 971 2-s2.0-77958584113 10.1038/nature09447
27. Veldhoen M., Hocking R. J., Atkins C. J., Locksley R. M., Stockinger B., TGF β in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006 24 2 179 189 2-s2.0-32244442562 10.1016/j.immuni.2006.01.001 (Pubitemid 43214587)
28. Lu M. O., Zhu J., The role of cytokines in Guillain-Barré syndrome. Journal of Neurology 2011 258 4 533 548 2-s2.0-79953831477 10.1007/s00415-010-5836-5
29. Nussinovitch U., Shoenfeld Y., The role of gender and organ specific autoimmunity. Autoimmunity Reviews 2012 11 6-7 A377 A385
30. Chiang H. L., Lyu R. K., Tseng M. Y., Chang K. H., Chang H. S., Hsu W. C., Kuo H. C., Chu C. C., Wu Y. R., Ro L. S., Huang C. C., Chen C. M., Analyses of transthyretin concentration in the cerebrospinal fluid of patients with Guillain-Barré syndrome and other neurological disorders. Clinica Chimica Acta 2009 405 1-2 143 147 2-s2.0-67349125374 10.1016/j.cca.2009.04.022
31. Kieseier B. C., Kiefer R., Gold R., Hemmer B., Willison H. J., Hartung H. P., Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle and Nerve 2004 30 2 131 156 2-s2.0-3242759811 10.1002/mus.20076 (Pubitemid 38982218)
32. Kebir H., Kreymborg K., Ifergan I., Dodelet-Devillers A., Cayrol R., Bernard M., Giuliani F., Arbour N., Becher B., Prat A., Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nature Medicine 2007 13 10 1173 1175 2-s2.0-34948909646 10.1038/nm1651 (Pubitemid 47530640)
33. Kamm C., Zettl U. K., Autoimmune disorders affecting both the central and peripheral nervous system. Autoimmunity Reviews 2012 11 3 196 202 2-s2.0-79959261014 10.1016/j.autrev.2011.05.012